Top

Published in:

01-08-2020 | Sarcopenia | Muscle and Bone (A Bonetto and M Brotto, Section Editors)

Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients’ Quality of Life

Authors: Marco Invernizzi, Alessandro de Sire, Stefano Carda, Konstantinos Venetis, Filippo Renò, Carlo Cisari, Nicola Fusco

Published in: Current Osteoporosis Reports | Issue 4/2020

Abstract

Purpose of Review

The goal of this review is to provide a comprehensive overview of (i) bone and muscle tissue modifications pathophysiology in spinal cord injury (SCI), (ii) experimental data on the physiopathological mechanisms underpinning these modifications and their similarities with the aging process, and (iii) potential clinical implications in the management of the disabling sequelae of SCI.

Recent Findings

Several studies attempted to describe the biology underpinning the links between bone and muscle tissues in the setting of highly disabling conditions, such as osteoporosis, sarcopenia, and neurodegenerative disorders, although these bidirectional connections remain still unclear.

Summary

SCI could be considered an in vivo paradigmatic model of the bone muscle interactions in unloading conditions that might be expanded in the field of neurodegenerative disorders or cancer studies. Future studies should take into consideration the newer insights into bone muscle crosstalk in order to develop multitargeted and therapeutic interventions.

Spinal Cord Injury (SCI) 2016 Facts and Figures at a Glance. J Spinal Cord Med. 2016;39(4):493–4. https://doi.org/10.1080/10790268.2016.1210925.

Carda S, Cisari C, Invernizzi M. Sarcopenia or muscle modifications in neurologic diseases: a lexical or patophysiological difference? Eur J Phys Rehabil Med. 2013;49(1):119–130.

Invernizzi M, de Sire A, Renò F, Cisari C, Runza L, Baricich A et al. Spinal Cord Injury as a Model of Bone-Muscle Interactions: Therapeutic Implications From in vitro and in vivo Studies. Front Endocrinol (Lausanne). 2020;11:204. https://doi.org/10.3389/fendo.2020.00204.

• Brotto M, Bonewald L. Bone and muscle: interactions beyond mechanical. Bone. 2015;80:109–14. https://doi.org/10.1016/j.bone.2015.02.010This review highlights the main biochemical interactions between bone and muscle tissues.CrossRefPubMedPubMedCentral

• Clark JM, Findlay DM. Musculoskeletal health in the context of spinal cord injury. Curr Osteoporos Rep. 2017;15(5):433–42. https://doi.org/10.1007/s11914-017-0400-1This review is focused on muscle wasting and bone loss in spinal cord injury, describing also their biochemical crosstalk.CrossRefPubMed

Aunan JR, Watson MM, Hagland HR, Soreide K. Molecular and biological hallmarks of ageing. Br J Surg. 2016;103(2):e29–46. https://doi.org/10.1002/bjs.10053.CrossRefPubMed

Ahuja CS, Nori S, Tetreault L, Wilson J, Kwon B, Harrop J, et al. Traumatic spinal cord injury-repair and regeneration. Neurosurgery. 2017;80(3s):S9–s22. https://doi.org/10.1093/neuros/nyw080.CrossRefPubMed

Varacallo M, Pizzutillo P. Osteoporosis in spinal cord injuries. StatPearls. Treasure Island: StatPearls PublishingStatPearls Publishing LLC; 2020.

Dionyssiotis Y. Is prophylaxis for osteoporosis indicated after acute spinal cord injury? Spinal Cord Ser Cases. 2019;5:24. https://doi.org/10.1038/s41394-019-0167-y.CrossRefPubMedPubMedCentral

10.

Lebrasseur NK, Achenbach SJ, Melton LJ 3rd, Amin S, Khosla S. Skeletal muscle mass is associated with bone geometry and microstructure and serum insulin-like growth factor binding protein-2 levels in adult women and men. J Bone Miner Res. 2012;27(10):2159–69. https://doi.org/10.1002/jbmr.1666.CrossRefPubMedPubMedCentral

11.

Nowlan NC, Bourdon C, Dumas G, Tajbakhsh S, Prendergast PJ, Murphy P. Developing bones are differentially affected by compromised skeletal muscle formation. Bone. 2010;46(5):1275–85. https://doi.org/10.1016/j.bone.2009.11.026.CrossRefPubMedPubMedCentral

12.

Rauch F, Bailey DA, Baxter-Jones A, Mirwald R, Faulkner R. The ‘muscle-bone unit’ during the pubertal growth spurt. Bone. 2004;34(5):771–5. https://doi.org/10.1016/j.bone.2004.01.022.CrossRefPubMed

13.

Soderpalm AC, Magnusson P, Ahlander AC, Karlsson J, Kroksmark AK, Tulinius M, et al. Bone mass development in patients with Duchenne and Becker muscular dystrophies: a 4-year clinical follow-up. Acta Paediatr. 2012;101(4):424–32. https://doi.org/10.1111/j.1651-2227.2011.02532.x.CrossRefPubMed

14.

Pereira FB, Leite AF, de Paula AP. Relationship between pre-sarcopenia, sarcopenia and bone mineral density in elderly men. Arch Endocrinol Metab. 2015;59(1):59–65. https://doi.org/10.1590/2359-3997000000011.CrossRefPubMed

15.

Sakellariou VI, Grigoriou E, Mavrogenis AF, Soucacos PN, Papagelopoulos PJ. Heterotopic ossification following traumatic brain injury and spinal cord injury: insight into the etiology and pathophysiology. J Musculoskelet Neuronal Interact. 2012;12(4):230–40.PubMed

16.

Wang L, Yao X, Xiao L, Tang X, Ding H, Zhang H, et al. The effects of spinal cord injury on bone healing in patients with femoral fractures. J Spinal Cord Med. 2014;37(4):414–9. https://doi.org/10.1179/2045772313y.0000000155.CrossRefPubMedPubMedCentral

17.

Maimoun L, Fattal C, Sultan C. Bone remodeling and calcium homeostasis in patients with spinal cord injury: a review. Metabolism. 2011;60(12):1655–63. https://doi.org/10.1016/j.metabol.2011.04.005.CrossRefPubMed

18.

Weaver FM, Etingen B, Guihan M, Ray C, Priebe M, Burns S, et al. Spinal cord injury providers' perspectives on managing sublesional osteoporosis. J Spinal Cord Med. 2019:1–7. https://doi.org/10.1080/10790268.2019.1704552.

19.

Lala D, Craven BC, Thabane L, Papaioannou A, Adachi JD, Popovic MR, et al. Exploring the determinants of fracture risk among individuals with spinal cord injury. Osteoporos Int. 2014;25(1):177–85. https://doi.org/10.1007/s00198-013-2419-1.CrossRefPubMed

20.

Giangregorio LM, Gibbs JC, Craven BC. Measuring muscle and bone in individuals with neurologic impairment; lessons learned about participant selection and pQCT scan acquisition and analysis. Osteoporos Int. 2016;27(8):2433–46. https://doi.org/10.1007/s00198-016-3572-0.CrossRefPubMed

21.

Yan Y, Wang L, Ge L, Pathak JL. Osteocyte-mediated translation of mechanical stimuli to cellular signaling and its role in bone and non-bone-related clinical complications. Curr Osteoporos Rep. 2020;18:67–80. https://doi.org/10.1007/s11914-020-00564-9.CrossRefPubMed

22.

Chikani V, Ho KK. Action of GH on skeletal muscle function: molecular and metabolic mechanisms. J Mol Endocrinol. 2014;52(1):R107–23. https://doi.org/10.1530/jme-13-0208.CrossRefPubMed

23.

Torrente Y, Bella P, Tripodi L, Villa C, Farini A. Role of insulin-like growth factor receptor 2 across muscle homeostasis: implications for treating muscular dystrophy. Cells. 2020;9(2). https://doi.org/10.3390/cells9020441.

24.

•• Bikle DD, Tahimic C, Chang W, Wang Y, Philippou A, Barton ER. Role of IGF-I signaling in muscle bone interactions. Bone. 2015;80:79–88. https://doi.org/10.1016/j.bone.2015.04.036This review provides an extremely detailed overview about IGF-I signaling in bone and muscle interactions.CrossRefPubMedPubMedCentral

25.

Takada Y, Takada YK, Fujita M. Crosstalk between insulin-like growth factor (IGF) receptor and integrins through direct integrin binding to IGF1. Cytokine Growth Factor Rev. 2017;34:67–72. https://doi.org/10.1016/j.cytogfr.2017.01.003.CrossRefPubMedPubMedCentral

26.

Hsieh YF, Turner CH. Effects of loading frequency on mechanically induced bone formation. J Bone Miner Res. 2001;16(5):918–24. https://doi.org/10.1359/jbmr.2001.16.5.918.CrossRefPubMed

27.

Laurent MR, Dubois V, Claessens F, Verschueren SM, Vanderschueren D, Gielen E, et al. Muscle-bone interactions: from experimental models to the clinic? A critical update. Mol Cell Endocrinol. 2016;432:14–36. https://doi.org/10.1016/j.mce.2015.10.017.CrossRefPubMed

28.

Shi Q, Chen Q, Pugno N, Li ZY. Effect of rehabilitation exercise durations on the dynamic bone repair process by coupling polymer scaffold degradation and bone formation. Biomech Model Mechanobiol. 2018;17(3):763–75. https://doi.org/10.1007/s10237-017-0991-6.CrossRefPubMed

29.

Frotzler A, Coupaud S, Perret C, Kakebeeke TH, Hunt KJ, Donaldson NN, et al. High-volume FES-cycling partially reverses bone loss in people with chronic spinal cord injury. Bone. 2008;43(1):169–76. https://doi.org/10.1016/j.bone.2008.03.004.CrossRefPubMed

30.

Duffell LD, Paddison S, Alahmary AF, Donaldson N, Burridge J. The effects of FES cycling combined with virtual reality racing biofeedback on voluntary function after incomplete SCI: a pilot study. J Neuroeng Rehabil. 2019;16(1):149. https://doi.org/10.1186/s12984-019-0619-4.CrossRefPubMedPubMedCentral

31.

Hemmatian H, Bakker AD, Klein-Nulend J, van Lenthe GH. Aging, osteocytes, and mechanotransduction. Curr Osteoporos Rep. 2017;15(5):401–11. https://doi.org/10.1007/s11914-017-0402-z.CrossRefPubMedPubMedCentral

32.

Imel EA, Biggin A, Schindeler A, Munns CF. FGF23, hypophosphatemia, and emerging treatments. JBMR Plus. 2019;3(8):e10190. https://doi.org/10.1002/jbm4.10190.CrossRefPubMedPubMedCentral

33.

•• Bonewald LF. The amazing osteocyte. J Bone Miner Res. 2011;26(2):229–38. https://doi.org/10.1002/jbmr.320This paper is one of the most detailed and comprehensive overviews about osteocyte functions.CrossRefPubMed

34.

Fukumoto S. FGF23 and bone and mineral metabolism. Handb Exp Pharmacol. 2019. https://doi.org/10.1007/164_2019_330.

35.

Sugiyama T, Saxon LK, Zaman G, Moustafa A, Sunters A, Price JS, et al. Mechanical loading enhances the anabolic effects of intermittent parathyroid hormone (1-34) on trabecular and cortical bone in mice. Bone. 2008;43(2):238–48. https://doi.org/10.1016/j.bone.2008.04.012.CrossRefPubMed

36.

Roberts MD, Santner TJ, Hart RT. Local bone formation due to combined mechanical loading and intermittent hPTH-(1-34) treatment and its correlation to mechanical signal distributions. J Biomech. 2009;42(15):2431–8. https://doi.org/10.1016/j.jbiomech.2009.08.030.CrossRefPubMed

37.

Maeda K, Kobayashi Y, Koide M, Uehara S, Okamoto M, Ishihara A, et al. The regulation of bone metabolism and disorders by Wnt signaling. Int J Mol Sci. 2019;20(22). https://doi.org/10.3390/ijms20225525.

38.

Weivoda MM, Youssef SJ, Oursler MJ. Sclerostin expression and functions beyond the osteocyte. Bone. 2017;96:45–50. https://doi.org/10.1016/j.bone.2016.11.024.CrossRefPubMed

39.

Honasoge M, Rao AD, Rao SD. Sclerostin: recent advances and clinical implications. Curr Opin Endocrinol Diabetes Obes. 2014;21(6):437–46. https://doi.org/10.1097/med.0000000000000114.CrossRefPubMed

40.

Morse LR, Sudhakar S, Danilack V, Tun C, Lazzari A, Gagnon DR, et al. Association between sclerostin and bone density in chronic spinal cord injury. J Bone Miner Res. 2012;27(2):352–9. https://doi.org/10.1002/jbmr.546.CrossRefPubMedPubMedCentral

41.

Morse LR, Sudhakar S, Lazzari AA, Tun C, Garshick E, Zafonte R, et al. Sclerostin: a candidate biomarker of SCI-induced osteoporosis. Osteoporos Int. 2013;24(3):961–8. https://doi.org/10.1007/s00198-012-2072-0.CrossRefPubMed

42.

Qin W, Li X, Peng Y, Harlow LM, Ren Y, Wu Y, et al. Sclerostin antibody preserves the morphology and structure of osteocytes and blocks the severe skeletal deterioration after motor-complete spinal cord injury in rats. J Bone Miner Res. 2015;30(11):1994–2004. https://doi.org/10.1002/jbmr.2549.CrossRefPubMed

43.

Beggs LA, Ye F, Ghosh P, Beck DT, Conover CF, Balaez A, et al. Sclerostin inhibition prevents spinal cord injury-induced cancellous bone loss. J Bone Miner Res. 2015;30(4):681–9. https://doi.org/10.1002/jbmr.2396.CrossRefPubMed

44.

Qin W, Zhao W, Li X, Peng Y, Harlow LM, Li J, et al. Mice with sclerostin gene deletion are resistant to the severe sublesional bone loss induced by spinal cord injury. Osteoporos Int. 2016;27(12):3627–36. https://doi.org/10.1007/s00198-016-3700-x.CrossRefPubMed

45.

Battaglino RA, Sudhakar S, Lazzari AA, Garshick E, Zafonte R, Morse LR. Circulating sclerostin is elevated in short-term and reduced in long-term SCI. Bone. 2012;51(3):600–5. https://doi.org/10.1016/j.bone.2012.04.019.CrossRefPubMedPubMedCentral

46.

Gifre L, Vidal J, Carrasco JL, Filella X, Ruiz-Gaspa S, Muxi A, et al. Effect of recent spinal cord injury on wnt signaling antagonists (sclerostin and dkk-1) and their relationship with bone loss. A 12-month prospective study. J Bone Miner Res. 2015;30(6):1014–21. https://doi.org/10.1002/jbmr.2423.CrossRefPubMed

47.

Invernizzi M, Carda S, Rizzi M, Grana E, Squarzanti DF, Cisari C, et al. Evaluation of serum myostatin and sclerostin levels in chronic spinal cord injured patients. Spinal Cord. 2015;53(8):615–20. https://doi.org/10.1038/sc.2015.61.CrossRefPubMed

48.

Chen H, Xu X, Liu M, Zhang W, Ke HZ, Qin A, et al. Sclerostin antibody treatment causes greater alveolar crest height and bone mass in an ovariectomized rat model of localized periodontitis. Bone. 2015;76:141–8. https://doi.org/10.1016/j.bone.2015.04.002.CrossRefPubMed

49.

Taut AD, Jin Q, Chung JH, Galindo-Moreno P, Yi ES, Sugai JV, et al. Sclerostin antibody stimulates bone regeneration after experimental periodontitis. J Bone Miner Res. 2013;28(11):2347–56. https://doi.org/10.1002/jbmr.1984.CrossRefPubMed

50.

Bramlett HM, Dietrich WD, Marcillo A, Mawhinney LJ, Furones-Alonso O, Bregy A, et al. Effects of low intensity vibration on bone and muscle in rats with spinal cord injury. Osteoporos Int. 2014;25(9):2209–19. https://doi.org/10.1007/s00198-014-2748-8.CrossRefPubMed

51.

Suresh A, Biswas A, Perumal S, Khurana S. Periostin and integrin signaling in stem cell regulation. Adv Exp Med Biol. 2019;1132:163–76. https://doi.org/10.1007/978-981-13-6657-4_16.CrossRefPubMed

52.

Bonnet N, Garnero P, Ferrari S. Periostin action in bone. Mol Cell Endocrinol. 2016;432:75–82. https://doi.org/10.1016/j.mce.2015.12.014.CrossRefPubMed

53.

Gerbaix M, Vico L, Ferrari SL, Bonnet N. Periostin expression contributes to cortical bone loss during unloading. Bone. 2015;71:94–100. https://doi.org/10.1016/j.bone.2014.10.011.CrossRefPubMed

54.

Bonnet N, Biver E, Durosier C, Chevalley T, Rizzoli R, Ferrari S. Additive genetic effects on circulating periostin contribute to the heritability of bone microstructure. J Clin Endocrinol Metab. 2015;100(7):E1014–21. https://doi.org/10.1210/jc.2015-1183.CrossRefPubMed

55.

Rousseau JC, Sornay-Rendu E, Bertholon C, Chapurlat R, Garnero P. Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study. J Clin Endocrinol Metab. 2014;99(7):2533–9. https://doi.org/10.1210/jc.2013-3893.CrossRefPubMed

56.

Kim BJ, Rhee Y, Kim CH, Baek KH, Min YK, Kim DY, et al. Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: clinical evidence for the different effects of periostin depending on the skeletal site. Bone. 2015;81:435–41. https://doi.org/10.1016/j.bone.2015.08.014.CrossRefPubMed

57.

Dumitru A, Radu BM, Radu M, Cretoiu SM. Muscle changes during atrophy. Adv Exp Med Biol. 2018;1088:73–92. https://doi.org/10.1007/978-981-13-1435-3_4.CrossRefPubMed

58.

Ghatas MP, Lester RM, Khan MR, Gorgey AS. Semi-automated segmentation of magnetic resonance images for thigh skeletal muscle and fat using threshold technique after spinal cord injury. Neural Regen Res. 2018;13(10):1787–95. https://doi.org/10.4103/1673-5374.238623.CrossRefPubMedPubMedCentral

59.

Ma W, Zhang R, Huang Z, Zhang Q, Xie X, Yang X, et al. PQQ ameliorates skeletal muscle atrophy, mitophagy and fiber type transition induced by denervation via inhibition of the inflammatory signaling pathways. Ann Transl Med. 2019;7(18):440. https://doi.org/10.21037/atm.2019.08.101.CrossRefPubMedPubMedCentral

60.

Gorgey AS, Witt O, O'Brien L, Cardozo C, Chen Q, Lesnefsky EJ, et al. Mitochondrial health and muscle plasticity after spinal cord injury. Eur J Appl Physiol. 2019;119(2):315–31. https://doi.org/10.1007/s00421-018-4039-0.CrossRefPubMed

61.

Kavazis AN, Morton AB, Hall SE, Smuder AJ. Effects of doxorubicin on cardiac muscle subsarcolemmal and intermyofibrillar mitochondria. Mitochondrion. 2017;34:9–19. https://doi.org/10.1016/j.mito.2016.10.008.CrossRefPubMed

62.

Rizzuto R, De Stefani D, Raffaello A, Mammucari C. Mitochondria as sensors and regulators of calcium signalling. Nat Rev Mol Cell Biol. 2012;13(9):566–78. https://doi.org/10.1038/nrm3412.CrossRefPubMed

63.

de Sire A, Baricich A, Reno F, Cisari C, Fusco N, Invernizzi M. Myostatin as a potential biomarker to monitor sarcopenia in hip fracture patients undergoing a multidisciplinary rehabilitation and nutritional treatment: a preliminary study. Aging Clin Exp Res. 2020;32(5):959–962. https://doi.org/10.1007/s40520-019-01436-8.

64.

Das DK, Graham ZA, Cardozo CP. Myokines in skeletal muscle physiology and metabolism: recent advances and future perspectives. Acta Physiol (Oxf). 2020;228(2):e13367. https://doi.org/10.1111/apha.13367.CrossRef

65.

Colaianni G, Cuscito C, Mongelli T, Pignataro P, Buccoliero C, Liu P, et al. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci U S A. 2015;112(39):12157–62. https://doi.org/10.1073/pnas.1516622112.CrossRefPubMedPubMedCentral

66.

Hanna MG, Badrising UA, Benveniste O, Lloyd TE, Needham M, Chinoy H, et al. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019;18(9):834–44. https://doi.org/10.1016/s1474-4422(19)30200-5.CrossRefPubMed

67.

Rose-John S. Interleukin-6 family cytokines. Cold Spring Harb Perspect Biol. 2018;10(2). https://doi.org/10.1101/cshperspect.a028415.

68.

Bank M, Stein A, Sison C, Glazer A, Jassal N, McCarthy D, et al. Elevated circulating levels of the pro-inflammatory cytokine macrophage migration inhibitory factor in individuals with acute spinal cord injury. Arch Phys Med Rehabil. 2015;96(4):633–44. https://doi.org/10.1016/j.apmr.2014.10.021.CrossRefPubMed

69.

Belizario JE, Fontes-Oliveira CC, Borges JP, Kashiabara JA, Vannier E. Skeletal muscle wasting and renewal: a pivotal role of myokine IL-6. Springerplus. 2016;5:619. https://doi.org/10.1186/s40064-016-2197-2.CrossRefPubMedPubMedCentral

70.

Merritt EK, Cross JM, Bamman MM. Inflammatory and protein metabolism signaling responses in human skeletal muscle after burn injury. J Burn Care Res. 2012;33(2):291–7. https://doi.org/10.1097/BCR.0b013e3182331e4b.CrossRefPubMedPubMedCentral

71.

Gamas L, Matafome P, Seica R. Irisin and myonectin regulation in the insulin resistant muscle: implications to adipose tissue: muscle crosstalk. J Diabetes Res. 2015;2015:359159–8. https://doi.org/10.1155/2015/359159.CrossRefPubMedPubMedCentral

72.

Wrann CD, White JP, Salogiannnis J, Laznik-Bogoslavski D, Wu J, Ma D, et al. Exercise induces hippocampal BDNF through a PGC-1alpha/FNDC5 pathway. Cell Metab. 2013;18(5):649–59. https://doi.org/10.1016/j.cmet.2013.09.008.CrossRefPubMedPubMedCentral

73.

Kammoun HL, Febbraio MA. Come on BAIBA light my fire. Cell Metab. 2014;19(1):1–2. https://doi.org/10.1016/j.cmet.2013.12.007.CrossRefPubMed

74.

Roberts LD, Bostrom P, O'Sullivan JF, Schinzel RT, Lewis GD, Dejam A, et al. Beta-aminoisobutyric acid induces browning of white fat and hepatic beta-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metab. 2014;19(1):96–108. https://doi.org/10.1016/j.cmet.2013.12.003.CrossRefPubMedPubMedCentral

75.

Kitase Y, Vallejo JA, Gutheil W, Vemula H, Jahn K, Yi J, et al. Beta-aminoisobutyric acid, l-BAIBA, is a muscle-derived osteocyte survival factor. Cell Rep. 2018;22(6):1531–44. https://doi.org/10.1016/j.celrep.2018.01.041.CrossRefPubMedPubMedCentral

76.

Elkasrawy MN, Hamrick MW. Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 2010;10(1):56–63.PubMedPubMedCentral

77.

Qin W, Bauman WA, Cardozo C. Bone and muscle loss after spinal cord injury: organ interactions. Ann N Y Acad Sci. 2010;1211:66–84. https://doi.org/10.1111/j.1749-6632.2010.05806.x.CrossRefPubMed

78.

Bauman WA, Cardozo CP. Osteoporosis in individuals with spinal cord injury. PM R. 2015;7(2):188–201; quiz. https://doi.org/10.1016/j.pmrj.2014.08.948.CrossRefPubMed

79.

Qin Y, Peng Y, Zhao W, Pan J, Ksiezak-Reding H, Cardozo C, et al. Myostatin inhibits osteoblastic differentiation by suppressing osteocyte-derived exosomal microRNA-218: a novel mechanism in muscle-bone communication. J Biol Chem. 2017;292(26):11021–33. https://doi.org/10.1074/jbc.M116.770941.CrossRefPubMedPubMedCentral

80.

Ushach I, Burkhardt AM, Martinez C, Hevezi PA, Gerber PA, Buhren BA, et al. METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages. Clin Immunol. 2015;156(2):119–27. https://doi.org/10.1016/j.clim.2014.11.006.CrossRefPubMed

81.

Rao RR, Long JZ, White JP, Svensson KJ, Lou J, Lokurkar I, et al. Meteorin-like is a hormone that regulates immune-adipose interactions to increase beige fat thermogenesis. Cell. 2014;157(6):1279–91. https://doi.org/10.1016/j.cell.2014.03.065.CrossRefPubMedPubMedCentral

82.

Jung TW, Lee SH, Kim HC, Bang JS, Abd El-Aty AM, Hacimuftuoglu A, et al. METRNL attenuates lipid-induced inflammation and insulin resistance via AMPK or PPARdelta-dependent pathways in skeletal muscle of mice. Exp Mol Med. 2018;50(9):122. https://doi.org/10.1038/s12276-018-0147-5.CrossRefPubMedPubMedCentral

83.

DiGirolamo DJ, Kiel DP, Esser KA. Bone and skeletal muscle: neighbors with close ties. J Bone Miner Res. 2013;28(7):1509–18. https://doi.org/10.1002/jbmr.1969.CrossRefPubMedPubMedCentral

84.

Mo C, Romero-Suarez S, Bonewald L, Johnson M, Brotto M. Prostaglandin E2: from clinical applications to its potential role in bone- muscle crosstalk and myogenic differentiation. Recent Pat Biotechnol. 2012;6(3):223–9. https://doi.org/10.2174/1872208311206030223.CrossRefPubMedPubMedCentral

85.

Brotto M. Editorial: welcome to our recent patents on biotechnology special edition on skeletal muscle diseases! Recent Pat Biotechnol. 2012;6(3):155–6. https://doi.org/10.2174/1872208311206030155.CrossRefPubMed

86.

Brotto M, Abreu EL. Sarcopenia: pharmacology of today and tomorrow. J Pharmacol Exp Ther. 2012;343(3):540–6. https://doi.org/10.1124/jpet.112.191759.

87.

Huang J, Hsu YH, Mo C, Abreu E, Kiel DP, Bonewald LF, et al. METTL21C is a potential pleiotropic gene for osteoporosis and sarcopenia acting through the modulation of the NF-kappaB signaling pathway. J Bone Miner Res. 2014;29(7):1531–40. https://doi.org/10.1002/jbmr.2200.CrossRefPubMedPubMedCentral

88.

Trajanoska K, Rivadeneira F, Kiel DP, Karasik D. Genetics of bone and muscle interactions in humans. Curr Osteoporos Rep. 2019;17(2):86–95. https://doi.org/10.1007/s11914-019-00505-1.CrossRefPubMedPubMedCentral

89.

Matsakas A, Nikolaidis MG, Kokalas N, Mougios V, Diel P. Effect of voluntary exercise on the expression of IGF-I and androgen receptor in three rat skeletal muscles and on serum IGF-I and testosterone levels. Int J Sports Med. 2004;25(7):502–8. https://doi.org/10.1055/s-2004-820945.CrossRefPubMed

90.

West DW, Burd NA, Staples AW, Phillips SM. Human exercise-mediated skeletal muscle hypertrophy is an intrinsic process. Int J Biochem Cell Biol. 2010;42(9):1371–5. https://doi.org/10.1016/j.biocel.2010.05.012.CrossRefPubMed

91.

Spangenburg EE, Le Roith D, Ward CW, Bodine SC. A functional insulin-like growth factor receptor is not necessary for load-induced skeletal muscle hypertrophy. J Physiol. 2008;586(1):283–91. https://doi.org/10.1113/jphysiol.2007.141507.CrossRefPubMed

92.

Adams GR, Haddad F, Bodell PW, Tran PD, Baldwin KM. Combined isometric, concentric, and eccentric resistance exercise prevents unloading-induced muscle atrophy in rats. J Appl Physiol (1985). 2007;103(5):1644–54. https://doi.org/10.1152/japplphysiol.00669.2007.CrossRef

93.

Hamrick MW, McNeil PL, Patterson SL. Role of muscle-derived growth factors in bone formation. J Musculoskelet Neuronal Interact. 2010;10(1):64–70.PubMedPubMedCentral

94.

Li G, Zhang L, Wang D, Luban AI, Jiang JX, Xu H, et al. Muscle-bone crosstalk and potential therapies for sarco-osteoporosis. J Cell Biochem. 2019;120(9):14262–73. https://doi.org/10.1002/jcb.28946.CrossRefPubMedPubMedCentral

95.

Kim JA, Roh E, Hong SH, Lee YB, Kim NH, Yoo HJ, et al. Association of serum sclerostin levels with low skeletal muscle mass: the Korean Sarcopenic obesity study (KSOS). Bone. 2019;128:115053. https://doi.org/10.1016/j.bone.2019.115053.CrossRefPubMed

96.

Hamrick MW, Shi X, Zhang W, Pennington C, Thakore H, Haque M, et al. Loss of myostatin (GDF8) function increases osteogenic differentiation of bone marrow-derived mesenchymal stem cells but the osteogenic effect is ablated with unloading. Bone. 2007;40(6):1544–53. https://doi.org/10.1016/j.bone.2007.02.012.CrossRefPubMedPubMedCentral

97.

Dankbar B, Fennen M, Brunert D, Hayer S, Frank S, Wehmeyer C, et al. Myostatin is a direct regulator of osteoclast differentiation and its inhibition reduces inflammatory joint destruction in mice. Nat Med. 2015;21(9):1085–90. https://doi.org/10.1038/nm.3917.CrossRefPubMed

98.

Oestreich AK, Carleton SM, Yao X, Gentry BA, Raw CE, Brown M, et al. Myostatin deficiency partially rescues the bone phenotype of osteogenesis imperfecta model mice. Osteoporos Int. 2016;27(1):161–70. https://doi.org/10.1007/s00198-015-3226-7.CrossRefPubMed

99.

Koncarevic A, Cornwall-Brady M, Pullen A, Davies M, Sako D, Liu J, et al. A soluble activin receptor type IIb prevents the effects of androgen deprivation on body composition and bone health. Endocrinology. 2010;151(9):4289–300. https://doi.org/10.1210/en.2010-0134.CrossRefPubMed

100.

Lala PK, Nandi P, Majumder M. Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer. Cancer Metastasis Rev. 2018;37(2–3):369–84. https://doi.org/10.1007/s10555-018-9734-0.CrossRefPubMed

101.

Invernizzi M, Rizzi M, Carda S, Cisari C, Molinari C, Reno F. Mini invasive skeletal muscle biopsy technique with a tri-axial end cut needle. Eur Rev Med Pharmacol Sci. 2015;19(13):2446–51.PubMed

102.

Giunta S. Exploring the complex relations between inflammation and aging (inflamm-aging): anti-inflamm-aging remodelling of inflamm- aging, from robustness to frailty. Inflamm Res. 2008;57(12):558–63. https://doi.org/10.1007/s00011-008-7243-2.CrossRefPubMed

103.

Livshits G, Kalinkovich A. Inflammaging as a common ground for the development and maintenance of sarcopenia, obesity, cardiomyopathy and dysbiosis. Ageing Res Rev. 2019;56:100980. https://doi.org/10.1016/j.arr.2019.100980.CrossRefPubMed

Title: Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients’ Quality of Life
Authors: Marco Invernizzi
Alessandro de Sire
Stefano Carda
Konstantinos Venetis
Filippo Renò
Carlo Cisari
Nicola Fusco
Publication date: 01-08-2020
Publisher: Springer US
Keywords: Sarcopenia
Osteoporosis
Osteoporosis
Published in: Current Osteoporosis Reports / Issue 4/2020
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-020-00601-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bone Muscle Crosstalk in Spinal Cord Injuries: Pathophysiology and Implications for Patients’ Quality of Life

Abstract

Purpose of Review

Recent Findings

Summary

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2020

Polycomb Repressive Complex 2: a Dimmer Switch of Gene Regulation in Calvarial Bone Development

Update on the Acute Effects of Glucose, Insulin, and Incretins on Bone Turnover In Vivo

Bone-Muscle Mutual Interactions

Correction to: New Developments in Fracture Risk Assessment

The Impact of Exercise on Bone Health in Type 2 Diabetes Mellitus—a Systematic Review

Muscle, Bone, and Fat Crosstalk: the Biological Role of Myokines, Osteokines, and Adipokines